Boule Diagnostics (BOUL) Stock Overview
Develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BOUL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Boule Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.15 |
| 52 Week High | SEK 10.60 |
| 52 Week Low | SEK 3.09 |
| Beta | 0.18 |
| 1 Month Change | -7.62% |
| 3 Month Change | -20.25% |
| 1 Year Change | -61.11% |
| 3 Year Change | -72.89% |
| 5 Year Change | -94.54% |
| Change since IPO | -73.13% |
Recent News & Updates
Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
There's been a notable change in appetite for Boule Diagnostics AB (publ) ( STO:BOUL ) shares in the week since its...Boule Diagnostics AB (publ)'s (STO:BOUL) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 0.4x Boule Diagnostics AB (publ) ( STO:BOUL ) may be sending very bullish...Recent updates
Shareholder Returns
| BOUL | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -5.1% | 0.1% | -1.1% |
| 1Y | -61.1% | -10.1% | 10.5% |
Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: BOUL underperformed the Swedish Market which returned 11.2% over the past year.
Price Volatility
| BOUL volatility | |
|---|---|
| BOUL Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 14.2% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: BOUL has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BOUL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 200 | Simonetta Tumbiolo | www.boule.com |
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms.
Boule Diagnostics AB (publ) Fundamentals Summary
| BOUL fundamental statistics | |
|---|---|
| Market cap | SEK 122.32m |
| Earnings (TTM) | -SEK 8.05m |
| Revenue (TTM) | SEK 478.39m |
Is BOUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOUL income statement (TTM) | |
|---|---|
| Revenue | SEK 478.39m |
| Cost of Revenue | SEK 275.98m |
| Gross Profit | SEK 202.41m |
| Other Expenses | SEK 210.46m |
| Earnings | -SEK 8.05m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 17, 2026
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 42.31% |
| Net Profit Margin | -1.68% |
| Debt/Equity Ratio | 105.1% |
How did BOUL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 03:38 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boule Diagnostics AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Christian Lee | Pareto Securities |